rVSVΔG/SARS-CoV-2-S-D614Gd21-NLucP is a recombinant vesicular stomatitis virus in which the native glycoprotein has been replaced with the SARS-CoV-2 Spike protein.
It is the responsibility of the principal investigator to seek Institutional Biosafety Safety Committee approval for recombinant DNA, transgenic animal or infectious agent use within their laboratory spaces and maintain an Institutional Biosafety Safety Committee approval during the time period these materials are used.
From the laboratory of Melinda A. Brindley, PhD, University of Georgia.
US customers - The USDA APHIS VS 16-6 or 16-6A permit must be obtained and a copy of the permit must be sent to Kerafast here, in advance of shipment. The Application Form VS 16-3 (Import controlled material import or transport organisms or vectors) must be submitted to USDA APHIS Veterinary Services to obtain the VS 16-6 or 16-6A permit.
Non-US customers - A BIS permit may be required in order to ship this product. Please Contact Us for more information
|Vector Information:||Virus was generated by transfecting the recombinant pVSV-d-G/ SARS-CoV-2-S_D614Gd21-NLucP plasmid along with VSV N, P, and L into BHK-T7 cells. Virus was then amplified on Vero cells. The virus encodes nano-luciferase-PEST (NLucP) which enables viral replication to be monitored with luciferase assays. The NLucP is not secreted, so cell lysates should be monitored.|
|Virus:||Recombinant vesicular stomatitis virus (rVSV)|
|Titer:||10^6 TCID50U/mL on Vero cells|
|Serotype:||VSV Indiana/SARS-CoV-2 Wuhan strain|
|Inoculation Conditions:||Produce stocks at low MOI (0.01) and harvest when >80% of the culture shows signs of cytopathic effect|
If you publish research with this product, please let us know so we can cite your paper.